利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.039 秒)

    N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS
    22.
    发明授权
    N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS 有权
    关于N-取代的桥接氨基亚甲基，双环的核酸类似物

    公开(公告)号：EP2170917B1

    公开(公告)日：2012-06-27

    申请号：EP08769651.4

    申请日：2008-05-22

    申请人： Isis Pharmaceuticals, Inc.

    发明人： PRAKASH, Thazha, P. ,  SWAYZE, Eric, E. ,  BHAT, Balkrishen

    IPC分类号： C07H19/04 ,  C07H21/00

    CPC分类号： C07H19/00 ,  C07H21/00

    摘要： Provided herein are bicyeMc nucleosides comprising a substituted amino group in the bridge, oligomeric compounds having at least one of these bi cyclic nucleosides and methods of using the oligomeric compounds. The bicyclic nucleosides comprising a substituted amino group in the bridge are useful for enhancing properties of oligomeric compounds including nuclease resistance, in certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

    TETRAHYDROPYRAN NUCLEIC ACID ANALOGS
    23.
    发明公开
    TETRAHYDROPYRAN NUCLEIC ACID ANALOGS 有权
    四氢吡喃核酸类似物

    公开(公告)号：EP2188298A2

    公开(公告)日：2010-05-26

    申请号：EP08798023.1

    申请日：2008-08-15

    申请人： Isis Pharmaceuticals, Inc.

    发明人： ALLERSON, Charles ,  BHAT, Balkrishen ,  PRAKASH, Thazha, P. ,  SWAYZE, Eric, E. ,  SIWKOWSKI, Andrew, M. ,  SETH, Punit, P.

    IPC分类号： C07H19/10 ,  C07H19/20 ,  C07H21/00 ,  C12N15/11

    CPC分类号： C12N15/113 ,  C07H19/10 ,  C07H19/20 ,  C07H21/00 ,  C12N15/111 ,  C12N2310/323 ,  C12N2320/51

    摘要： The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

    摘要翻译： 本公开描述了四氢吡喃核苷类似物，由其制备的寡聚化合物以及使用该寡聚化合物的方法。 更具体地说，提供了具有一个或多个手性取代基的四氢​​吡喃核苷类似物，其可用于增强寡聚化合物的性质，包括核酸酶抗性和结合亲和力。 在一些实施方案中，本文提供的寡聚化合物与靶RNA的一部分杂交，导致靶RNA的正常功能丧失。

    N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS
    24.
    发明公开
    N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS 有权
    关于N-取代的桥接氨基亚甲基，双环的核酸类似物

    公开(公告)号：EP2170917A2

    公开(公告)日：2010-04-07

    申请号：EP08769651.4

    申请日：2008-05-22

    申请人： Isis Pharmaceuticals, Inc.

    发明人： PRAKASH, Thazha, P. ,  SWAYZE, Eric, E. ,  BHAT, Balkrishen

    IPC分类号： C07H19/04 ,  C07H21/00

    CPC分类号： C07H19/00 ,  C07H21/00

    摘要： Provided herein are bicyeMc nucleosides comprising a substituted amino group in the bridge, oligomeric compounds having at least one of these bi cyclic nucleosides and methods of using the oligomeric compounds. The bicyclic nucleosides comprising a substituted amino group in the bridge are useful for enhancing properties of oligomeric compounds including nuclease resistance, in certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

    NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE
    27.
    发明公开
    NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE 审中-公开
    病毒性RNA依赖的RNA聚合酶的核苷作为抑制剂

    公开(公告)号：EP1572945A2

    公开(公告)日：2005-09-14

    申请号：EP03751779.4

    申请日：2003-06-23

    申请人： Merck & Co., Inc. ,  ISIS PHARMACEUTICALS, INC.

    发明人： OLSEN, David, B. ,  MACCOSS, Malcolm ,  BHAT, Balkrishen ,  ELDRUP, Anne, B.

    IPC分类号： C12N1/00

    CPC分类号： C07H19/22 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20

    摘要： The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.